Outcomes of extremely low birth weight infants

Pediatrics

Volumn 98, Issue 5, 1996, Pages 931-937

  Hack, Maureen ^a   Friedman, Harriet ^b   Fanaroff, Avroy A ^b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b NONE

Author keywords

development; outcome; surfactant; very low birth weight

Indexed keywords

DEXAMETHASONE; LUNG SURFACTANT;

ARTICLE; CHILD GROWTH; FOLLOW UP; HUMAN; INFANT; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; RESPIRATORY DISTRESS SYNDROME; SURVIVAL RATE; TREATMENT OUTCOME;

CAUSE OF DEATH; CESAREAN SECTION; CHILD DEVELOPMENT; FEMALE; GESTATIONAL AGE; HUMANS; INFANT MORTALITY; INFANT, NEWBORN; INFANT, PREMATURE, DISEASES; INFANT, VERY LOW BIRTH WEIGHT; PERINATAL CARE; PREGNANCY; SURVIVAL RATE;

EID: 0029970691     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Allen MC, Donohue PK, Dusman AE. The limit of viability - neonatal outcome of infants born at 22 to 25 weeks' gestation. N Engl J Med. 1993;329:1597-1601
2. Merritt TA. Surfactant therapy in extremely premature infants. J Pediatr. 1994;125:172-173
3. Hack M, Fanaroff AA. Outcomes of extremely immature infants - a perinatal dilemma. N Engl J Med. 1993;329:1649-1650
4. Hack M, Fanaroff A. Delivery room care of the fetal infant: effects on morbidity and outcome. N Engl J Med. 1986;314:660-664
5. Hack M, Fanaroff AA. Outcomes of extremely-low-birth-weight infants between 1982 and 1988. N Engl J Med. 1989;321:1642-1647
6. Jobe AH. Pulmonary surfactant therapy. N Engl J Med. 1993;328:861-868
7. Cummings JJ, D'Eugenio DB, Gross SJ. A controlled trial of dexamethasone in preterm infants at high risk for bronchopulmonary dysplasia. N Engl J Med. 1989;320:1505-1510
8. Horbar JD, Wright LL, Soll RF, et al. A multicenter randomized trial comparing two surfactants for the treatment of neonatal respiratory distress syndrome. J Pediatr. 1993;123:757-766
9. World Health Organization. Recommended definitions, terminology and format for statistical tables related to the perinatal period and use of a new certificate for cause of perinatal deaths: modifications recommended by FIGO as amended October 14, 1976. Acta Obstet Gynecol Scand. 1977;56:247-253
10. Hack M, Horbar JD, Malloy MH, Tyson JE, Wright L, Wright E. Very low birthweight outcomes of the NICHD. neonatal network. Pediatrics. 1991;87:587-597
11. Goldenberg RL, Davis RO, Cutter GR, Hoffman HJ, Brumfield CG, Foster JM. Prematurity, postdates, and growth retardation: the influence of use of ultrasonography on reported gestational age. Am J Obstet Gynecol. 1989;160:462-470
12. Bayley N. Bayley Scales of Infant Development. 2nd ed. San Antonio, TX: Psychological Corporation; 1993
13. Usher R, McLean F. Intrauterine growth of live-born Caucasian infants at sea level: standards obtained from measurements in seven dimensions of infants born between 25 and 44 weeks of gestation. J Pediatr. 1969;74:901-910
14. Synnes AR, Ling EWY, Whitfield MF, et al. Perinatal outcomes of a large cohort of extremely low gestational age infants (twenty-three to twenty-eight completed weeks of gestation). J Pediatr. 1994;125:952-960
15. Pomerance JJ, Pomerance LJ, Mekjian MZ. Cost/intact infant of infants weighing 500-749 g at birth in 50 gram increments: preliminary data. Pediatr Res. 1994;35:283A. Abstract
16. Davis DJ. How aggressive should delivery room cardiopulmonary resuscitation be for extremely low birth weight infants? Pediatrics. 1993; 92:447-450
17. Ferrara TB, Hoekstra RE, Couser RJ, et al. Survival and follow-up of infants born at 23 to 26 weeks of gestational age: effects of surfactant therapy. J Pediatr. 1994;124:119-124
18. Msall ME, Buck GM, Rogers BT, et al. Multivariate risks among extremely premature infants. J Perinatol. 1994;14:41-47
19. Fanaroff AA, Wright LL, Stevenson DK, et al. Very low birthweight outcomes of the NICHD Neonatal Network May 1991-December 1992. Am J Obstet Gynecol 1995;173:1423-1431
20. Schwartz RM, Luby AM, Scanlon JW, Kellogg RJ. Effect of surfactant on morbidity, mortality, and resource use in newborn infants weighing 500 to 1500 g. N Engl J Med. 1994;330:1476-1480
21. Palta M, Weinstein MR, McGuinness G, Gabbert D, Brady W, Peters ME. Mortality and morbidity after availability of surfactant therapy. Arch Pediatr Adolesc Med. 1994;148:1295-1301
22. The Investigators of the Vermont-Oxford Trials Network Database Project. The Vermont-Oxford Trials Network. Very low birth weight outcomes for 1990. Pediatrics. 1993;91:1-6
23. Philip AGS. Neonatal mortality rate: is further improvement possible? J Pediatr. 1995;125:427-433
24. Asztolas EEV, Zayack MD, Shennan AT. Is there room for optimism? 2 year outcome in premature infants born under 30 weeks gestation in a regional perinatal center (1988-1991). Pediatr Res. 1994;35:213A. Abstract
25. Stevenson D, Walther F, Long W, et al. Controlled trial of a single dose of synthetic surfactant at birth in premature infants weighing 500 to 699 grams. J Pediatr. 1992;120:S3-S12
26. Liechty EA, Donovan E, Purohit D, et al. Reduction of neonatal mortality after multiple doses of bovine surfactant in low birth weight neonates with respiratory distress syndrome. Pediatrics. 1991;88:19-28
27. Hoekstra RE, Jackson JC, Myers TF, et al. Improved neonatal survival following multiple doses of bovine surfactant in very premature neonates at risk for respiratory distress syndrome. Pediatrics. 1991;88:10-18
28. Katz VL, Bose CL. Improving survival of the very premature infant. J Perinatol. 1993;13:261-265
29. Kesler K, Krywanio M. Increasing survival of extremely low birth-weight infants in Alaska. Alaska Med. 1992;34:167-172
30. Ferrara TB, Hoekstra RE, Gaziano E, Knox GE, Couser RJ, Fangman JJ. Changing outcome of extremely premature infants (<26 weeks' gestation and <750 gm): survival and follow-up at a tertiary center. Am J Obstet Gynecol. 1989;161:1114-1118
31. National Institutes of Health. Effect of Corticosteroids for Fetal Maturation on Perinatal Outcomes. NIH Consensus Statement. Bethesda, MD: National Institutes of Health; 1994;12:1-24
32. Jobe AH, Mitchell BR, Gunkel JH. Beneficial effects of the combined use of prenatal Corticosteroids and postnatal surfactant on preterm infants. Am J Obstet Gynecol. 1993;168:508-513
33. Egan EA, Kwong MS, Notter RH. Clinical trial of tracheal instillation of calf lung lipid (CLL) at birth to prevent hyaline membrane disease (HMD). Pediatr Res. 1985;21:340A. Abstract
34. Garite TJ, Rumney PJ, Briggs GG, et al. A randomized, placebo-controlled trial of betamethasone for the prevention of respiratory distress syndrome at 24 to 28 weeks' gestation. Am J Obstet Gynecol. 1992;166:646-651
35. Ringer SA, Choi YY. Efficacy of antenatal corticosteroid therapy (ACS) in extremely premature infants. Pediatr Res. 1995;35:251A. Abstract
36. Hack M, Taylor HG, Klein N, Eiben R, Schatschneider C, Mercuri Minich N. School age outcomes in children with birth weights under 750 g. N Engl J Med. 1994;331:753-759
37. Ferrara TB, Hoekstra RE, Couser RJ, et al. Effects of surfactant therapy on outcome of infants with birth weights of 600 to 750 grams. J Pediatr. 1991;119:455-457
38. Gunkel JH, Banks PLC. Surfactant therapy and intracranial hemorrhage: review of the literature and results of new analyses. Pediatrics. 1993;92:775-786
39. Casiro OG, Bingham W, MacMurray B, et al. Double-blind one-year follow-up of 89 infants with birth weights of 500-749 grams and respiratory distress syndrome randomized to two rescue doses of synthetic surfactant or air placebo: improved developmental outcome. J Pediatr. 1995;126:553-560
40. LaPine T, Jackson JC, Bennett FC. Outcome of infants weighing less then 800 gm at birth: 15 years experience. Pediatrics. 1995;96:479-483
41. McCormick MC. Has the prevalence of handicapped infants increased with the improved survival of the very low birth weight infant? Clin Perinatol. 1993;20:263-277
42. Silverman WA. The line between "knowing" and "doing": medicine's dilemma at the end of the twentieth century. Arch Dis Child. 1994;71: 261-265